Anzeige
Mehr »
Login
Freitag, 27.09.2024 Börsentäglich über 12.000 News von 691 internationalen Medien
Gold – der nächste große Gewinner? Warum Analysten diese Aktie im Blick haben
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJXX | ISIN: US18914F1030 | Ticker-Symbol: 7QD
Tradegate
27.09.24
08:10 Uhr
2,530 Euro
-0,025
-0,98 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLOVER HEALTH INVESTMENTS CORP Chart 1 Jahr
5-Tage-Chart
CLOVER HEALTH INVESTMENTS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
2,5372,58113:23
2,5332,59113:11
GlobeNewswire (Europe)
52 Leser
Artikel bewerten:
(0)

Clover Health Investments, Corp.: Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation.

Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operations and technology. Most recently, he served as COO at Jefferson Health Plans, where he spearheaded the creation of a Business Process as a Service (BPaaS) offering, Prior to that, Mr. Brand held senior roles at Horizon Blue Cross Blue Shield of New Jersey, where he played a key role in transforming healthcare delivery and supporting New Jersey physicians. His extensive knowledge of the New Jersey market reinforces Clover Health's commitment to enhancing the quality of care in the state and investing in local healthcare infrastructure.

"As a proud lifelong New Jerseyan, I'm truly impressed by Clover's unwavering dedication to our state," said Brand. "By championing independent physicians, Clover strengthens the core of our local communities, and their affordable plans provide seniors with vital access to high-quality healthcare. After years of insight into the healthcare system, I firmly believe Clover has transformed New Jersey into one of the leading states for Medicare beneficiaries."

Throughout his career, Mr. Brand has demonstrated a proven track record of success in driving large-scale operational transformations, optimizing costs, and implementing innovative solutions to improve business performance. During his tenure at Jefferson Health Plans, he was instrumental in building scalable processes to support Medicare Advantage and Medicaid programs and integrating advanced technology such as AI and automation into day-to-day operations. At Horizon Blue Cross Blue Shield of NJ, Mr. Brand led enterprise-wide technology initiatives, including the transformation of critical systems, and helped steer the organization toward digital innovation and enhanced customer experiences.

In his new role at Clover Health, Mr. Brand will be responsible for managing Clover's Medicare Advantage operations with a focus on optimizing operational processes to enhance performance and drive the company's value-based care initiatives through advanced technology and data-driven solutions.

"Joe's appointment underscores Clover's unwavering commitment to operational excellence and supporting local healthcare providers," said Jamie Reynoso, CEO of Medicare Advantage, Clover Health. "His vast experience in driving efficiency and utilizing cutting-edge solutions will be instrumental in elevating our Medicare Advantage operations and ensuring outstanding service for our members and the physicians we partner with across New Jersey."

For information on Clover Health's Medicare Advantage plans, visit www.cloverhealth.com. For information on Clover Health Investments, Corp. visit investors.cloverhealth.com.

About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Press Contact:
Andrew Still-Baxter
press@cloverhealth.com

Investor Relations Contact:
Ryan Schmidt
investors@cloverhealth.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.